Liverpool houses the MRC-supported Centre for Drug Safety Science (CDSS), a Centre of Excellence, which has developed an integrated chemical, biochemical, molecular, cellular and genetic approach to analyse the fundamental and complex mechanisms of clinically important adverse drug reactions (ADRs) in clinical samples, in vitro models and in vivo models.
The Centre has a matrix approach for:
- The collection and biobanking of clinical material
- The construction of experimental methods with appropriate statistical and informatic modelling
- The application of state-of-the-art qualitative and quantitative bioanalytical methodologies to define the chemical, biological and genetic basis of clinically-relevant ADRs, which allows evaluation of both well established and newly emerging safety issues.